© Magnific
May 13, 2026
Marianne Waldenfels
- Health
Ozempic and Wegovy in Breast Cancer: Study Suggests Improved Survival
New study suggests GLP-1 medications like Ozempic and Wegovy could improve breast cancer prognosis.
Share article:
© Magnific
May 13, 2026
Marianne Waldenfels
New study suggests GLP-1 medications like Ozempic and Wegovy could improve breast cancer prognosis.
Find a DoctorSearch the network for suitable specialists and contact them directly
Women with breast cancer who took GLP-1 medications such as Ozempic or Wegovy, had lower mortality and a reduced risk of recurrence in a new observational study. The findings are drawing significant attention in the medical community, although experts caution against interpreting the data as proof of a protective effect.
The analysis, published in JAMA Network Open, examined a large cohort of breast cancer patients and compared women who received GLP-1 receptor agonists with those who did not. According to the authors, use of the medications was associated with a lower risk of death from any cause as well as a lower risk of tumor recurrence.
The results were particularly striking in women with obesity or type 2 diabetes.
Some of the most well-known GLP-1 medications include Ozempic, Wegovy, and Mounjaro. These active ingredients are primarily used for the treatment of type 2 diabetes and obesity and have been the focus of intensive research for months.
Obesity and metabolic disorders are considered factors that can affect the course of many cancers negatively. Therefore, a possible positive effect of GLP-1 therapies seems at least biologically plausible.
Additionally, GLP-1 receptor agonists not only lower weight and blood sugar, but can also reduce cardiometabolic risks. This could be relevant for breast cancer patients, as cardiovascular diseases also play an important role in long-term mortality.
Despite the much-discussed results, this is not a randomized clinical trial, but a retrospective observational analysis. Therefore, it cannot be definitively proven that the drugs themselves caused the observed advantage.
A new US study found an unusually high rate of colon polyps among marathon and ultramarathon runners. What do the findings really mean, and should endurance athletes be concerned? A gastroenterologist explains.
Christine Bürg & Marianne Waldenfels
Carrot juice and coconut water are being hailed on TikTok as the secret to a natural summer glow. Beta-carotene can indeed alter skin tone — though not in the way many social media videos suggest. A dermatologist explains what the science actually shows.
Christine Bürg & Marianne Waldenfels
With
Dr. med. Timm Golüke
Artificial intelligence is taking over routine tasks and freeing up time for what truly matters: the relationship between doctor and patient. Prof. Dr. Dominik Pförringer explains why empathy is becoming the most important factor for success in medicine in the age of AI.
Prof. Dominik Pförringer
By
Univ.-Prof. Dr. med. Dominik Pförringer
Prevention should not only detect diseases early — it should stop them from developing in the first place. Dr. Jan Hennigs explains which examinations are genuinely worthwhile today, why cardiovascular risks are so often underestimated, and how artificial intelligence is set to transform the field of prevention.
Christine Bürg & Marianne Waldenfels
An interview with
Dr. med. Jan K. Hennigs
Such datasets are considered susceptible to so-called confounders and biases. Patients with GLP-1 therapy often differ in important respects from other patients - for example, in general health status, access to medical care, or treatment intensity.
A professional commentary by Medscape also points out that administrative data and incomplete documentation can significantly limit the validity. If key factors such as tumor biology, surgical status, or adjuvant therapies are not fully captured, reliable comparisons are difficult.
The current data should therefore not be understood as proof that GLP-1 medications directly influence breast cancer or protect against relapses.
Rather, the study suggests that the relationship between metabolic health, weight loss, and cancer progression should be examined more closely. Experts see this as an important approach for further research.
For the treatment of breast cancer there are currently no immediate changes. GLP-1 medications remain primarily drugs for the treatment of type 2 diabetes and obesity – not for cancer treatment.
However, the results emphasize how important prospective and randomized studies would be to more precisely examine the potential effects of the drugs and clearly distinguish between drug effects, weight loss, and general health differences.
